9月15日（周一），MIRXES-B午后涨超20%，创历史新高，较招股价23.3港元已涨超150%。截至发稿，涨21%，报53.14港元，成交额5.8亿港元。
消息面上，根据8月22日恒生指数公司公告，Mirxes觅瑞获纳入恒生综合指数。相关变动已于9月8日起生效，该公司也正式成为沪港通下港股通标的。公开资料显示，Mirxes是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场触手可及。
截至最后实际可行日期，集团拥有一种核心产品(即GASTROClearTM)、两种其他商业化产品(即LUNGClearTM及FortitudeTM)及六种处于临床前阶段的候选产品。据悉，集团的核心产品GASTROClearTM为一个由12种miRNA生物标志物组成的用于胃癌筛查的基于血液的miRNA检测组。该产品已于2019年5 月获得新加坡卫生科学局(HSA)的C类体外诊断(IVD)证书后在新加坡成功商业化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
